{"title":"criszanlizumab用于预防镰状细胞病的危重","authors":"S. Chaplin","doi":"10.1002/psb.2012","DOIUrl":null,"url":null,"abstract":"Crizanlizumab (Adakveo) is a new monoclonal antibody therapy for the prevention of recurrent vaso‐occlusive crises in patients with sickle cell disease. This article discusses its mode of action, efficacy and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Crizanlizumab to prevent crises in sickle cell disease\",\"authors\":\"S. Chaplin\",\"doi\":\"10.1002/psb.2012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Crizanlizumab (Adakveo) is a new monoclonal antibody therapy for the prevention of recurrent vaso‐occlusive crises in patients with sickle cell disease. This article discusses its mode of action, efficacy and place in therapy.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Crizanlizumab to prevent crises in sickle cell disease
Crizanlizumab (Adakveo) is a new monoclonal antibody therapy for the prevention of recurrent vaso‐occlusive crises in patients with sickle cell disease. This article discusses its mode of action, efficacy and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
